Diabetic foot ulcers pipeline review, h1 2014

334 views
279 views

Published on

This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
334
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Diabetic foot ulcers pipeline review, h1 2014

  1. 1. Diabetic Foot Ulcers - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 diabetic Foot Ulcers Overview 10 therapeutics Development 11 pipeline Products For Diabetic Foot Ulcers Overview 11 pipeline Products For Diabetic Foot Ulcers Comparative Analysis 12 diabetic Foot Ulcers Therapeutics Under Development By Companies 13 diabetic Foot Ulcers Therapeutics Under Investigation By Universities/institutes 17 diabetic Foot Ulcers Pipeline Products Glance 18 late Stage Products 18 clinical Stage Products 19 early Stage Products 20 unknown Stage Products 21 diabetic Foot Ulcers Products Under Development By Companies 22 diabetic Foot Ulcers Products Under Investigation By Universities/institutes 24 diabetic Foot Ulcers Companies Involved In Therapeutics Development 25 derma Sciences, Inc. 25 cardium Therapeutics, Inc. 26 glaxosmithkline Plc 27 cardiovascular Biotherapeutics, Inc. 28 stratatech Corporation 29 photopharmica Limited 30 tissue Med Biosciences 31 reliance Life Sciences Pvt. Ltd. 32 nanotherapeutics, Inc. 33 celgene Corporation 34 kaken Pharmaceutical Co., Ltd. 35 cytotools Ag 36 indus Biotech Private Limited 37 Diabetic Foot Ulcers - Pipeline Review, H1 2014
  2. 2. phage Pharmaceuticals, Inc. 38 novalead Pharma Pvt. Ltd. 39 firststring Research, Inc. 40 theravasc, Inc. 41 coda Therapeutics, Inc. 42 adocia 43 eyegene, Inc. 44 izun Pharmaceuticals Corporation 45 praxis Pharmaceuticals Inc. 46 oneness Biotech Co., Ltd. 47 aprogen, Inc. 48 pergamum Ab 49 dipexium Pharmaceuticals Llc 50 kasiak Research Pvt. Ltd. 51 diabetic Foot Ulcers Therapeutics Assessment 52 assessment By Monotherapy Products 52 assessment By Target 53 assessment By Mechanism Of Action 56 assessment By Route Of Administration 59 assessment By Molecule Type 61 drug Profiles 64 pexiganan Acetate - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 dermapro Ci-05 - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 trafermin - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 wh-1 - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 dsc-127 - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 cvbt-141b - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 doxycycline - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 gam-501 - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 biochaperone Pdgf-bb - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 coda-001 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 px-070101 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 reliderm-dt - Drug Profile 82 product Description 82 mechanism Of Action 82 Diabetic Foot Ulcers - Pipeline Review, H1 2014
  3. 3. r&d Progress 82 ppa-904 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 izn-6d4 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 granexin - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 cstc-1 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 esmolol Hydrochloride - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 gentamicin Sulfate - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 gsk-1278863 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 fibroblast Growth Factor-1 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 pda-002 - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 tmbp-3 - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 coagulation Factor Xiva (human) - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 rusalatide Acetate - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 indus-820 - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 vld-02 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 ap-102 - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 drug For Wound Healing - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 stromal Cell Therapy For Diabetic Complications - Drug Profile 104 product Description 104 mechanism Of Action 104 Diabetic Foot Ulcers - Pipeline Review, H1 2014
  4. 4. r&d Progress 104 eg-decorin - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 nu-2 - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 mt-003 - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 ca5-hif Gene Therapy For Wound And Ulcers - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 cathelicidin - Drug Profile 109 product Description 109 mechanism Of Action 109 r&d Progress 109 drug For Diabetic Foot Ulcer - Drug Profile 111 product Description 111 mechanism Of Action 111 r&d Progress 111 ll-37 - Drug Profile 112 product Description 112 mechanism Of Action 112 r&d Progress 112 refaheal - Drug Profile 113 product Description 113 mechanism Of Action 113 r&d Progress 113 diabetic Foot Ulcers Recent Pipeline Updates 114 diabetic Foot Ulcers Dormant Projects 125 diabetic Foot Ulcers Discontinued Products 126 diabetic Foot Ulcers Product Development Milestones 127 featured News & Press Releases 127 jan 16, 2014: Derma Sciences Provides Update On Dsc127 Phase 3 Clinical Trials 127 oct 10, 2013: Pergamum Announces Final Data From Phase I/ii Study Of Ll-37 In Patients With Chronic Leg Ulcers 127 sep 10, 2013: Dipexium Provides Locilex Manufacturing Update 128 jul 09, 2013: Dipexium Pharmaceuticals Announces The Issuance Of A New U.s. Patent For Locilex 129 jun 18, 2013: Daewoong Pharma Enters Into Contract With Abdi Ibrahim To Export Easyef To Turkey 129 apr 25, 2013: Derma Sciences Begins Screening Patients In Second Phase Iii Trial With Dsc127 For Healing Diabetic Foot Ulcers 130 mar 18, 2013: Adocia Announces Phase Iii Development Program For Treatment Of Diabetic Foot Ulcer 131 feb 06, 2013: Derma Sciences Initiates Enrollment In Dsc127 Phase Iii Trial For Healing Diabetic Foot Ulcers 131 jan 16, 2013: Dermatools Biotech Launches Phase Iii Clinical Trial With Dermapro For Treatment Of Diabetic Foot Syndrome 133 jan 03, 2013: Dipexium Pharma Receives Special Protocol Assessment From Fda For Phase Iii Trial In Mildly Infected Diabetic Foot Ulcers With Locilex 133 appendix 135 methodology 135 coverage 135 secondary Research 135 primary Research 135 expert Panel Validation 135 contact Us 136 disclaimer 136 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Diabetic Foot Ulcers - Pipeline Review, H1 2014
  5. 5. Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Diabetic Foot Ulcers - Pipeline Review, H1 2014

×